Therapeutic options in minimizing left ventricular hypertrophy

American Heart Journal

Volumn 139, Issue 1 II, 2000, Pages

  Devereux, Richard B ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; NIFEDIPINE; RAMIPRIL; RENIN; TRANDOLAPRIL; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY RISK; DRUG MECHANISM; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK;

EID: 0033987656     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.102902     Document Type: Review

References (29)

1. Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 1983;68:470-6.
2. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008.
3. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
4. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998;32:1454-9.
5. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
6. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
7. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995;273:1592-7.
8. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998;31:1635-40.
9. Devereux RB, Okin PM, Roman MJ. Pre-clinical cardiovascular disease and surrogate end-points in hypertension: does race influence target organ damage independent of blood pressure? Ethn Dis 1998;8:138-48.
10. Rowlands DB, Glover DR, Ireland MA, et al. Assessment of left-ventricular mass and its response to antihypertensive treatment. Lancet 1982;1:467-70.
11. Post WS, Larson MG, Myers RH, et al. Heritability of left ventricular mass: the Framingham Heart Study. Hypertension 1997;30:1025-8.
12. Devereux RB, Roman MJ, De Simone G, et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997;96:1416-23.
13. Harrap SB, Dominiczak AF, Fraser R, et al. Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. Circulation 1996;93:1148-54.
14. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90:1786-93.
15. Jacobi J, Schlaich MP, Delles C, et al. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999;12:418-22.
16. Schlaich MP, Schobel HP, Langenfeld MR, et al. Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol 1998;49:153-9.
17. Nagano M, Higaki J, Mikami H, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991;9:595-9.
18. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
19. 1 expression. Hypertension 1994;23:587-92.
20. De Simone G, Devereux RB, Camargo MJF, et al. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 1996;9:216-22.
21. Thürmann PA, Kenedi P, Schmidt A, et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037-42.
22. Devereux RB, Agabiti-Rosei E, Dahlöf B, et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials [published erratum appears in J Hypertens 1997;15:103, J Hypertens Suppl 1996;14:S95-102.
23. Devereux RB, Dahlof B, Levy D, et al. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996;78:61-5.
24. Dahlöf B, Devereux R, deFaire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods: the LIFE Study Group. Am J Hypertens 1997;10:705-13.
25. Gosse P, Guez D, Guéret P, et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998;16:531-5.
26. Mann J, Julius S, for the VALUE Trial Group. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension: rationale and design. Blood Press 1998;7:176-83.
27. Pitt B. Regression of left ventricular hypertrophy in patients with hypertension: blockade of the renin-angiotensin-aldosterone system [editorial]. Circulation 1998;98:1987-9.
28. Kahan T, Malmqvist K, Edner M, et al. Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade [abstract 857-4]. J Am Coll Cardiol 1998;31:212A.
29. Campbell SV, Rizzo V, Di Maio F, et al. Antihypertensive therapy with losartan and fosinopril: efficacy in left ventricular hypertrophy regression [abstract E120]. J Hypertens 1998;11:125A.